<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Leukoencephalopathy due to heroin use</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Leukoencephalopathy due to heroin use</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Leukoencephalopathy due to heroin use</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy T Waldman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although heroin use by inhalation ("chasing the dragon") can be traced back to the 1950s [<a href="#rid1">1</a>], the leukoencephalopathy and neurologic symptoms associated with this method of heroin abuse were initially described in 1982 in a report from the Netherlands [<a href="#rid2">2</a>]. Subsequent reports suggest that leukoencephalopathy can also develop with heroin injection or snorting [<a href="#rid3">3,4</a>].</p><p>This topic will discuss the pathogenesis, clinical features, diagnosis, and management of heroin leukoencephalopathy due to inhalation or other routes of intake.</p><p>Other aspects of heroin abuse are described separately. (See  <a class="medical medical_review" href="/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a> and  <a class="medical medical_review" href="/d/html/108803.html" rel="external">"Opioid use disorder: Treatment overview"</a>.)</p><p class="headingAnchor" id="H2586873130"><span class="h1">TERMINOLOGY AND DESCRIPTION</span><span class="headingEndMark"> — </span>"Chasing the dragon" is a method of heroin vapor inhalation that is distinct from smoking or sniffing heroin [<a href="#rid1">1,5</a>]. Other names for this process include "chinesing" and "Chinese blowing." A small amount of heroin powder is placed on aluminum foil, which is then heated by placing a match or lighter underneath. The white powder becomes a reddish-brown gelatinous substance that releases a thick, white smoke, which resembles a dragon's tail. The fumes are "chased" or inhaled through a straw or small tube [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Heroin and its metabolite, 6-monoacetylmorphine (6-MAM), are hydrolyzed to <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, which is then conjugated to morphine-3-glucuronide and morphine-6-glucuronide. Plasma levels of heroin and its metabolites are detected after inhalation [<a href="#rid7">7</a>], and morphine and morphine-3-glucuronide are detectable in cerebrospinal fluid (CSF) after chronic systemic use [<a href="#rid8">8</a>]. Heroin and its metabolites cross the blood-brain barrier; however, the mechanism of neurologic injury related to heroin inhalation is unknown.</p><p>Since heroin leukoencephalopathy is observed less frequently among users who inject or snort heroin [<a href="#rid3">3,4</a>], it is possible that unknown toxins contained in the heroin pyrolysate (the product of chemical change caused by heating) are implicated in the condition [<a href="#rid5">5</a>]. However, the neuropathology was not replicated in rats exposed to this compound [<a href="#rid2">2</a>]. Triethyl tin (TET), a component of inorganic tin, was also suspected since TET poisoning results in vacuolar white matter edema [<a href="#rid5">5,9</a>], but an etiologic role for TET is unlikely, since the TET content in aluminum foil is negligible [<a href="#rid5">5</a>].</p><p>Aluminum toxicity has also been suspected as the etiology. However, when patients on dialysis were exposed to a contaminated water supply, the neurologic symptoms of aluminum toxicity differed from heroin leukoencephalopathy. Affected individuals presented with mental status changes and seizures, progressing, in some, to death [<a href="#rid10">10</a>]. An earlier pathology report of a fatal encephalopathy in dialysis patients linked the syndrome to aluminum accumulation in brain gray matter (unlike the white matter pathology seen in leukoencephalopathy) [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/1839.html" rel="external">"Aluminum toxicity in chronic kidney disease", section on 'Acute encephalopathy'</a>.)</p><p>Mitochondrial dysfunction may play a role in the development of heroin leukoencephalopathy, as suggested by mitochondrial changes in specimens from brain biopsy [<a href="#rid2">2</a>], by elevated lactate on magnetic resonance spectroscopy [<a href="#rid5">5</a>], and by the clinical improvement associated with antioxidant therapy that has been reported in a few patients [<a href="#rid5">5</a>]. (See <a class="local">'Treatment'</a> below.)</p><p>In this syndrome, parkinsonian symptoms may be caused by reversible inhibition of tetrahydrobiopterin metabolism; tetrahydrobiopterin is required for the conversion of tyrosine to levodopa, the precursor of dopamine, and for the conversion of tryptophan to serotonin [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Despite the prevalence of heroin abuse, only 160 cases of leukoencephalopathy due to heroin inhalation (chasing the dragon) had been reported by the year 2018 [<a href="#rid3">3</a>]. However, inhaled heroin use may be on the rise. In a different review that identified 50 heroin abusers who developed leukoencephalopathy, the main route of use was inhalation (60 percent), but a substantial proportion used heroin by intravenous injection (30 percent) or snorting (10 percent) [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Heroin leukoencephalopathy has a variable clinical spectrum associated with a spongiform leukoencephalopathy.</p><p class="headingAnchor" id="H3789601876"><span class="h2">Presentation and course</span><span class="headingEndMark"> — </span>In a review of 50 patients with leukoencephalopathy associated with heroin use, cerebellar ataxia and dysarthria were the predominant symptoms in users who inhaled heroin, while altered mental status, mutism, and urinary or fecal incontinence were predominant in users who injected heroin [<a href="#rid4">4</a>].</p><p>The largest study, a 2018 review of the literature of patients with confirmed acute heroin inhalation leukoencephalopathy, identified 88 cases [<a href="#rid3">3</a>]. These were divided into three levels of clinical severity (mild, moderate, or severe [<a href="#rid13">13</a>]):</p><p class="bulletIndent1"><span class="glyph">●</span>A mild syndrome, characterized by inattentiveness, confusion, ataxia, and psychomotor symptoms, in 21 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A moderate syndrome, characterized by corticospinal or extrapyramidal involvement and severe confusion or delirium, in 52 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A severe syndrome, characterized by generalized motor impairment, apathy/abulia without language disorders or apraxia, and impaired alertness, in 27 percent; death ensued in two-thirds of these cases (see <a class="local">'Prognosis'</a> below)</p><p></p><p>In the initial cohort of 47 heroin vapor inhalers from the Netherlands, the leukoencephalopathy occurred in three stages [<a href="#rid2">2</a>]. In the first stage, the initial symptoms (in order of decreasing frequency) were:</p><p class="bulletIndent1"><span class="glyph">●</span>Soft/pseudobulbar speech</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebellar ataxia</p><p class="bulletIndent1"><span class="glyph">●</span>Motor restlessness</p><p class="bulletIndent1"><span class="glyph">●</span>Apathy/abulia/bradyphrenia</p><p></p><p>After two to four weeks, approximately half of the patients progressed to the second (intermediate) stage, which was characterized by rapid worsening of cerebellar symptoms and additional features [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pyramidal tract signs</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperactive reflexes</p><p class="bulletIndent1"><span class="glyph">●</span>Spastic hemiplegia or quadriplegia</p><p class="bulletIndent1"><span class="glyph">●</span>Tremor and myoclonus</p><p class="bulletIndent1"><span class="glyph">●</span>Chorea and athetosis</p><p></p><p>A few weeks later, one-fourth of the initial cohort entered the terminal stage and developed the following symptoms before death ensued [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>"Stretching spasms"</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotonic/areflexic paresis</p><p class="bulletIndent1"><span class="glyph">●</span>Akinetic mutism</p><p class="bulletIndent1"><span class="glyph">●</span>Central pyrexia</p><p></p><p>Various features of parkinsonism, in some cases reversible, may be seen as early or late manifestations of heroin leukoencephalopathy [<a href="#rid2">2,5,12</a>]. These include bradykinesia, tremor, chorea, short festinating steps, masked facies, soft speech, cogwheel rigidity, and loss of postural reflexes.</p><p>Communicating and obstructive hydrocephalus, requiring neurosurgical intervention, have been described as complications of heroin inhalation in case reports [<a href="#rid14">14,15</a>].</p><p>Once symptoms develop, progression of disease can continue for a few weeks up to six months in the absence of continued exposure [<a href="#rid2">2,5,16</a>], a phenomenon called "coasting" [<a href="#rid17">17</a>].</p><p>While most individuals have had a subacute presentation, three patients presented with acute change in mental status requiring intubation (for airway protection) despite normal respirations [<a href="#rid18">18</a>]. The diagnosis of heroin-induced inhalation leukoencephalopathy was confirmed through history, laboratory testing, and imaging.</p><p class="headingAnchor" id="H5"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Brain MRI (<a class="graphic graphic_diagnosticimage graphicRef103815" href="/d/graphic/103815.html" rel="external">image 1</a>) shows diffuse, symmetrical white matter hyperintensities on T2 and fluid-attenuated inversion recovery (FLAIR) sequences in the cerebellum, posterior cerebrum, and posterior limbs of the internal capsule. There can be additional signal abnormalities in the splenium of the corpus callosum, the corticospinal tracts, the lemniscal pathway in the brainstem, and the hippocampus [<a href="#rid5">5,19-22</a>]. Increased signal in periventricular white matter may be present on diffusion-weighted images with corresponding low signal on apparent diffusion coefficient (ADC) maps [<a href="#rid23">23</a>], perhaps due to vacuolization rather than infarction. Most patients demonstrate T2 shine-through with increased ADC signal [<a href="#rid24">24</a>].</p><p>With heroin inhalation, a posterior-anterior gradient is typically seen in the supratentorial white matter, and the frontal lobes are therefore relatively spared [<a href="#rid4">4,5</a>]. However, with significant heroin abuse, there may be frontal lobe involvement.</p><p>Heroin inhalation by other modalities (ie, sniffing, snorting, or smoking) and intravenous heroin use may cause symmetric, confluent T2 and FLAIR hyperintense lesions on brain MRI in the frontoparietal white matter (often involving the subcortical U-fibers), centrum semiovale, and genu of the internal capsule [<a href="#rid4">4,25-27</a>]. The brainstem and cerebellum are often spared, distinguishing these abnormalities from the imaging characteristics observed in chasing the dragon.</p><p>Magnetic resonance spectroscopy abnormalities in three patients with heroin leukoencephalopathy included abnormally elevated lactate, suggesting mitochondrial dysfunction in the affected white matter and decreased levels of N-acetyl aspartate and choline in the white matter, gray matter, and cerebellum [<a href="#rid5">5,22</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>Electroencephalography in two severely affected patients showed moderate diffuse slowing with excess delta, consistent with a global encephalopathy [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Neuropathology</span><span class="headingEndMark"> — </span>Pathologic data from autopsy cases as well as brain biopsies reveal spongiform degeneration of white matter with relative sparing of subcortical U-fibers, and vacuole formation in oligodendroglia and myelin sheaths visible with electron microscopy. Axons are typically spared, and demyelination is not a prominent feature. The deep white matter is edematous, but inflammation is absent. Mitochondria are also abnormal [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of heroin inhalation leukoencephalopathy is clinical and should be suspected in patients with a history of heroin use, especially if by inhalation, who present with acute or subacute onset of neurologic abnormalities. These may include one or more of the following features [<a href="#rid2">2,5,19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebellar, pyramidal, or extrapyramidal signs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurobehavioral changes, including confusion, apathy/abulia, or motor restlessness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutism and/or incontinence</p><p></p><p>The diagnosis is supported by the characteristic neuroimaging findings (see <a class="local">'Neuroimaging'</a> above). A positive urine test for <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> is supportive of heroin use in the preceding 48 to 96 hours. The presence of the metabolite 6-monoacetylmorphine (6-MAM) is specific for heroin. However, 6-MAM is detectable for only two to eight hours after heroin use. Therefore, the absence of 6-MAM in urine that is positive for opioids does not rule out the use of heroin [<a href="#rid3">3</a>].</p><p>Diagnostic uncertainty is increased when the method of heroin abuse or history of exposure is unknown.</p><p>Proposed diagnostic criteria for heroin leukoencephalopathy due to inhalation (chasing the dragon) consist of the following [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Inclusion criteria:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>1) Presence of a clinical syndrome suggestive of leukoencephalopathy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>2) Positive heroin toxicology testing</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>3) Heroin use confirmed by the patient, his or her next of kin, or a witness</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>4) Supportive neuroimaging</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>5) Neuropathology findings consistent with spongiform leukoencephalopathy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exclusion criteria:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Confirmed history of acute intoxication or exposure to a toxin other than heroin that can cause a chasing the dragon-like outcome</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Overt clinical picture suggesting an infectious, demyelinating, vascular, or paraneoplastic cause</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neuroimaging consistent with predominantly cortical involvement along with sparing of subcortical areas and posterior fossa</p><p></p><p>The diagnosis of chasing the dragon is considered definite if the patient fulfills all of the inclusion criteria; probable if the patient fulfills inclusion criteria 1 through 4, and possible if only inclusion criteria 1 through 3 are met, or if criteria 1 through 4 are met but are accompanied by confirmed polysubstance abuse or heroin abuse by multiple routes [<a href="#rid3">3</a>]. While postmortem neuropathology remains the gold standard for diagnosis, brain biopsy is discouraged in clinical practice.</p><p class="headingAnchor" id="H9"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Heroin addiction has been associated with a number of neurologic conditions [<a href="#rid28">28</a>], including brain abscess [<a href="#rid29">29</a>], transverse myelitis [<a href="#rid30">30,31</a>], neuropathy [<a href="#rid32">32,33</a>], and rhabdomyolysis with myoglobinuria [<a href="#rid31">31,34,35</a>]. However, these disorders are not likely to be confused with leukoencephalopathy.</p><p class="headingAnchor" id="H4032901688"><span class="h2">Leukoencephalopathy</span><span class="headingEndMark"> — </span>Leukoencephalopathy may occur after global anoxic-ischemic injury or after toxic exposure to a variety of agents, including the following [<a href="#rid13">13,36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Antineoplastic agents (cranial irradiation, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9206" href="/d/drug information/9206.html" rel="external">carmustine</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, levamisole, <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9992" href="/d/drug information/9992.html" rel="external">thiotepa</a>, interleukin-2, interferon alfa)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppressive drugs (<a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobial agents (amphotericin B, <a class="drug drug_general" data-topicid="8523" href="/d/drug information/8523.html" rel="external">hexachlorophene</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs of abuse (toluene, ethanol, cocaine, 3,4-methylenedioxymethamphetamine, intravenous heroin, inhaled heroin pyrolysate, psilocybin, benzodiazepines)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Environmental toxins (carbon monoxide, arsenic, carbon tetrachloride)</p><p></p><p>The acronym "CHOICES" has been proposed as an aid to remembering the causes of acute toxic leukoencephalopathy [<a href="#rid37">37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>C – Chemotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>H – Heroin-induced</p><p class="bulletIndent1"><span class="glyph">●</span>O – Opioid analog use</p><p class="bulletIndent1"><span class="glyph">●</span>I – Immunosuppressant or imidazole medications</p><p class="bulletIndent1"><span class="glyph">●</span>C – "Crack" cocaine abuse</p><p class="bulletIndent1"><span class="glyph">●</span>E – Environmental (carbon monoxide) and ethanol-related</p><p class="bulletIndent1"><span class="glyph">●</span>S – Splenial lesions associated with use of antiseizure, chemotherapy, and immunosuppressant medications</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Anoxic-ischemic injury</span><span class="headingEndMark"> — </span>Global anoxia or ischemia, which can be precipitated by drug overdose or cardiopulmonary arrest, typically affects the gray matter in the cerebral cortex and various subcortical structures, such as the globus pallidus, with the cerebellum less frequently involved [<a href="#rid38">38-40</a>].</p><p>Cerebral white matter damage may occur with anoxic-ischemic injury, particularly after prolonged hypoxia and hypotension [<a href="#rid39">39</a>]. The radiologic appearance of white matter damage may be delayed [<a href="#rid40">40</a>]. Nevertheless, there are reports of early preferential involvement of white matter after anoxic-ischemic injury [<a href="#rid41">41,42</a>]. In addition, drug overdose from intravenous heroin use has been reported as a cause of anoxic-ischemic leukoencephalopathy [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Drugs of abuse</span><span class="headingEndMark"> — </span>Varying degrees of white matter injury may be found in chronic abusers of heroin, alcohol, and toluene [<a href="#rid13">13</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic alcohol abuse is associated with white matter damage. Alcohol abusers, including those with liver disease and Wernicke encephalopathy, lose a disproportionate amount of subcortical white matter compared with cortical gray matter. Marchiafava-Bignami disease is a rare disorder of demyelination or necrosis of the corpus callosum and adjacent subcortical white matter that occurs predominantly in malnourished individuals with alcohol use disorder. (See  <a class="medical medical_review" href="/d/html/4840.html" rel="external">"Overview of the chronic neurologic complications of alcohol", section on 'Marchiafava-Bignami disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic toluene abuse from inhalation of vapor in glue ("glue sniffing"), paint, and paint thinner is associated with neurologic impairment, including dementia and selective white matter injury [<a href="#rid43">43</a>]. Widespread white matter hyperintensity is seen on brain MRI in severely affected patients with toluene leukoencephalopathy. (See  <a class="medical medical_review" href="/d/html/6502.html" rel="external">"Inhalant misuse in children and adolescents"</a>.)</p><p></p><p>A case report described a severe diffuse leukoencephalopathy that followed methylenedioxymethamphetamine (MDMA, also called ecstasy) use and respiratory insufficiency [<a href="#rid44">44</a>]. However, the relative contribution of anoxic-ischemic injury compared with the leukoencephalopathy is unclear.</p><p class="headingAnchor" id="H12"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There is no proven treatment for heroin leukoencephalopathy.</p><p>Empiric antioxidant therapy (with either coenzyme Q10 [300 mg four times a day] alone, or coenzyme Q10 in combination with <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> [2000 mg daily] and <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> [2000 mg daily]) has been used to treat nine patients with heroin inhalation leukoencephalopathy [<a href="#rid5">5,19,45-48</a>], with varying improvement in five and deterioration or no change in four [<a href="#rid5">5,49</a>].</p><p>Given these data, the absence of proven treatment, and the low likelihood of serious side effects, we suggest antioxidant therapy with the combination of coenzyme Q10, <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a>, and <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> for patients with heroin leukoencephalopathy.</p><p class="headingAnchor" id="H618500784"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The severity of disease probably depends on the duration and cumulative amount of heroin inhaled, as well as presence of comorbidities, including other substance abuse.</p><p>In the 2018 systematic review of heroin inhalation, with outcome data for 83 cases, 17 patients (20 percent) died; details of the cause of death were often unreported [<a href="#rid3">3</a>]. Nearly all the deaths occurred among the 24 patients with severe symptoms, where 16 (67 percent) died. Among 42 patients with moderate symptoms, only one patient (2 percent) died. There were no deaths among the 17 patients with mild symptoms.</p><p>Patients who survive often require physical and drug rehabilitation.</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>"Chasing the dragon" is a method of heroin vapor inhalation that is distinct from smoking or sniffing heroin and is associated with leukoencephalopathy. (See <a class="local">'Terminology and description'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mechanism of neurologic injury related to heroin use is unknown. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial symptoms of heroin leukoencephalopathy include soft speech, ataxia, motor restlessness, bradyphrenia, and apathy/abulia. Some patients develop progressive disease with later occurrence of pyramidal signs, hyperactive reflexes, pseudobulbar palsy, spastic paresis, tremor, myoclonus, chorea, and athetosis. Severe disease is characterized by fever, akinetic mutism, spasms, hypotonia, areflexia, and death. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brain magnetic resonance imaging (MRI) (<a class="graphic graphic_diagnosticimage graphicRef103815" href="/d/graphic/103815.html" rel="external">image 1</a>) shows diffuse, symmetrical white matter hyperintensities on T2 and fluid-attenuated inversion recovery (FLAIR) sequences with a posterior to anterior gradient of involvement; the frontal lobes may be relatively spared. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuropathology reveals spongiform degeneration; demyelination is not a prominent feature. (See <a class="local">'Neuropathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of heroin inhalation leukoencephalopathy is clinical, and is supported by the characteristic neuroimaging findings. The differential diagnosis includes leukoencephalopathy following global anoxic-ischemic injury or exposure to other drugs of abuse. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although there is no proven treatment for heroin leukoencephalopathy, we suggest antioxidant therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The suggested regimen is coenzyme Q10 (300 mg four times a day), <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> (2000 mg daily), and <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> (2000 mg daily). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H103724555"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Alan Percy, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Strang J, Griffiths P, Gossop M. Heroin smoking by 'chasing the dragon': origins and history. Addiction 1997; 92:673.</a></li><li><a class="nounderline abstract_t">Wolters EC, van Wijngaarden GK, Stam FC, et al. Leucoencephalopathy after inhaling "heroin" pyrolysate. Lancet 1982; 2:1233.</a></li><li><a class="nounderline abstract_t">Alambyan V, Pace J, Miller B, et al. The Emerging Role of Inhaled Heroin in the Opioid Epidemic: A Review. JAMA Neurol 2018; 75:1423.</a></li><li><a class="nounderline abstract_t">Cheng MY, Chin SC, Chang YC, et al. Different routes of heroin intake cause various heroin-induced leukoencephalopathies. J Neurol 2019; 266:316.</a></li><li><a class="nounderline abstract_t">Kriegstein AR, Shungu DC, Millar WS, et al. Leukoencephalopathy and raised brain lactate from heroin vapor inhalation ("chasing the dragon"). Neurology 1999; 53:1765.</a></li><li><a class="nounderline abstract_t">Keogh CF, Andrews GT, Spacey SD, et al. Neuroimaging features of heroin inhalation toxicity: "chasing the dragon". AJR Am J Roentgenol 2003; 180:847.</a></li><li><a class="nounderline abstract_t">Rook EJ, van Ree JM, van den Brink W, et al. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin Pharmacol Toxicol 2006; 98:86.</a></li><li><a class="nounderline abstract_t">Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000; 27:524.</a></li><li><a class="nounderline abstract_t">Squibb RE, Carmichael NG, Tilson HA. Behavioral and neuromorphological effects of triethyl tin bromide in adult rats. Toxicol Appl Pharmacol 1980; 55:188.</a></li><li><a class="nounderline abstract_t">Berend K, van der Voet G, Boer WH. Acute aluminum encephalopathy in a dialysis center caused by a cement mortar water distribution pipe. Kidney Int 2001; 59:746.</a></li><li><a class="nounderline abstract_t">Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976; 294:184.</a></li><li><a class="nounderline abstract_t">Heales S, Crawley F, Rudge P. Reversible parkinsonism following heroin pyrolysate inhalation is associated with tetrahydrobiopterin deficiency. Mov Disord 2004; 19:1248.</a></li><li><a class="nounderline abstract_t">Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med 2001; 345:425.</a></li><li><a class="nounderline abstract_t">Bui DH, Pace J, Manjila S, et al. Heroin inhalation complicated by refractory hydrocephalus: A novel presentation. Neurology 2015; 84:2093.</a></li><li><a class="nounderline abstract_t">Dastur CK, Chang GY. Heroin inhalation complicated by refractory hydrocephalus: A novel presentation. Neurology 2015; 85:2083.</a></li><li><a class="nounderline abstract_t">Sempere AP, Posada I, Ramo C, Cabello A. Spongiform leucoencephalopathy after inhaling heroin. Lancet 1991; 338:320.</a></li><li><a class="nounderline abstract_t">Berger AR, Schaumburg HH, Schroeder C, et al. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology 1992; 42:1367.</a></li><li><a class="nounderline abstract_t">Achamallah N, Wright RS, Fried J. Chasing the wrong dragon: A new presentation of heroin-induced toxic leukoencephalopathy mimicking anoxic brain injury. J Intensive Care Soc 2019; 20:80.</a></li><li><a class="nounderline abstract_t">Long H, Deore K, Hoffman RS, Nelson LS. A fatal case of spongiform leukoencephalopathy linked to "chasing the dragon". J Toxicol Clin Toxicol 2003; 41:887.</a></li><li><a class="nounderline abstract_t">Weber W, Henkes H, Möller P, et al. Toxic spongiform leucoencephalopathy after inhaling heroin vapour. Eur Radiol 1998; 8:749.</a></li><li><a class="nounderline abstract_t">Gupta PK, Krishnan PR, Sudhakar PJ. Hippocampal involvement due to heroin inhalation--"chasing the dragon". Clin Neurol Neurosurg 2009; 111:278.</a></li><li><a class="nounderline abstract_t">Offiah C, Hall E. Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy. Clin Radiol 2008; 63:146.</a></li><li><a class="nounderline abstract_t">McKinney AM, Kieffer SA, Paylor RT, et al. Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol 2009; 193:192.</a></li><li><a class="nounderline abstract_t">Hagel J, Andrews G, Vertinsky T, et al. "Chasing the dragon"--imaging of heroin inhalation leukoencephalopathy. Can Assoc Radiol J 2005; 56:199.</a></li><li><a class="nounderline abstract_t">Blasel S, Hattingen E, Adelmann M, et al. Toxic leukoencephalopathy after heroin abuse without heroin vapor inhalation: MR imaging and clinical features in three patients. Clin Neuroradiol 2010; 20:48.</a></li><li><a class="nounderline abstract_t">Lefaucheur R, Lebas A, Gérardin E, et al. Leucoencephalopathy following abuse of sniffed heroin. J Clin Neurosci 2017; 35:70.</a></li><li><a class="nounderline abstract_t">Herrmann Z, Jaini P, Hsu J, Rush AJ. Two Cases Comparing the Presentations and Outcomes of Heroin-induced Toxic Leukoencephalopathy. J Psychiatr Pract 2022; 28:426.</a></li><li><a class="nounderline abstract_t">Hill MD, Cooper PW, Perry JR. Chasing the dragon--neurological toxicity associated with inhalation of heroin vapour: case report. CMAJ 2000; 162:236.</a></li><li><a class="nounderline abstract_t">Hershewe GL, Davis LE, Bicknell JM. Primary cerebellar brain abscess from nocardiosis in a heroin addict. Neurology 1988; 38:1655.</a></li><li><a class="nounderline abstract_t">Richter RW, Rosenberg RN. Transverse myelitis associated with heroin addiction. JAMA 1968; 206:1255.</a></li><li><a class="nounderline abstract_t">Sahni V, Garg D, Garg S, et al. Unusual complications of heroin abuse: transverse myelitis, rhabdomyolysis, compartment syndrome, and ARF. Clin Toxicol (Phila) 2008; 46:153.</a></li><li><a class="nounderline abstract_t">Amnueilaph R, Boongird P, Leechawengwongs M, Vejjajiva A. Heroin neuropathy. Lancet 1973; 1:1517.</a></li><li><a class="nounderline abstract_t">Loizou LA, Boddie HG. Polyradiculoneuropathy associated with heroin abuse. J Neurol Neurosurg Psychiatry 1978; 41:855.</a></li><li><a class="nounderline abstract_t">Schreiber SN, Liebowitz MR, Bernstein LH, Srinivasan K. Limb compression and renal impairment (crush syndrome) complicating narcotic overdose. N Engl J Med 1971; 284:368.</a></li><li><a class="nounderline abstract_t">de Gans J, Stam J, van Wijngaarden GK. Rhabdomyolysis and concomitant neurological lesions after intravenous heroin abuse. J Neurol Neurosurg Psychiatry 1985; 48:1057.</a></li><li><a class="nounderline abstract_t">Aljarallah S, Al-Hussain F. Acute fatal posthypoxic leukoencephalopathy following benzodiazepine overdose: a case report and review of the literature. BMC Neurol 2015; 15:69.</a></li><li><a class="nounderline abstract_t">Koksel Y, Ozutemiz C, Rykken J, et al. "CHOICES": An acronym to aid in delineating potential causes of non-metabolic, non-infectious acute toxic leukoencephalopathy. Eur J Radiol Open 2019; 6:243.</a></li><li class="breakAll">Meyer A. Intoxication. In: Greenfield's Neuropathology, Blackwood W, McMenemey WH, Meyer A, et al (Eds), Williams &amp; Wilkins, Baltimore 1967.</li><li><a class="nounderline abstract_t">Ginsberg MD, Hedley-Whyte ET, Richardson EP Jr. Hypoxic-ischemic leukoencephalopathy in man. Arch Neurol 1976; 33:5.</a></li><li><a class="nounderline abstract_t">Sawada H, Udaka F, Seriu N, et al. MRI demonstration of cortical laminar necrosis and delayed white matter injury in anoxic encephalopathy. Neuroradiology 1990; 32:319.</a></li><li><a class="nounderline abstract_t">Chalela JA, Wolf RL, Maldjian JA, Kasner SE. MRI identification of early white matter injury in anoxic-ischemic encephalopathy. Neurology 2001; 56:481.</a></li><li><a class="nounderline abstract_t">Molloy S, Soh C, Williams TL. Reversible delayed posthypoxic leukoencephalopathy. AJNR Am J Neuroradiol 2006; 27:1763.</a></li><li><a class="nounderline abstract_t">Filley CM, Halliday W, Kleinschmidt-DeMasters BK. The effects of toluene on the central nervous system. J Neuropathol Exp Neurol 2004; 63:1.</a></li><li><a class="nounderline abstract_t">Bertram M, Egelhoff T, Schwarz S, Schwab S. Toxic leukencephalopathy following "ecstasy" ingestion. J Neurol 1999; 246:617.</a></li><li><a class="nounderline abstract_t">Gacouin A, Lavoue S, Signouret T, et al. Reversible spongiform leucoencephalopathy after inhalation of heated heroin. Intensive Care Med 2003; 29:1012.</a></li><li><a class="nounderline abstract_t">Jee RC, Tsao WL, Shyu WC, et al. Heroin vapor inhalation-induced spongiform leukoencephalopathy. J Formos Med Assoc 2009; 108:518.</a></li><li><a class="nounderline abstract_t">Cordova JP, Balan S, Romero J, et al. 'Chasing the dragon': new knowledge for an old practice. Am J Ther 2014; 21:52.</a></li><li><a class="nounderline abstract_t">Bartlett E, Mikulis DJ. Chasing "chasing the dragon" with MRI: leukoencephalopathy in drug abuse. Br J Radiol 2005; 78:997.</a></li><li><a class="nounderline abstract_t">Kriegstein AR, Armitage BA, Kim PY. Heroin inhalation and progressive spongiform leukoencephalopathy. N Engl J Med 1997; 336:589.</a></li></ol></div><div id="topicVersionRevision">Topic 1696 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9246796" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Heroin smoking by 'chasing the dragon': origins and history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6128545" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Leucoencephalopathy after inhaling "heroin" pyrolysate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29987325" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Emerging Role of Inhaled Heroin in the Opioid Epidemic: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30478618" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Different routes of heroin intake cause various heroin-induced leukoencephalopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10563626" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Leukoencephalopathy and raised brain lactate from heroin vapor inhalation ("chasing the dragon")</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12591709" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neuroimaging features of heroin inhalation toxicity: "chasing the dragon".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16433897" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10874511" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7423503" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Behavioral and neuromorphological effects of triethyl tin bromide in adult rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168958" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acute aluminum encephalopathy in a dialysis center caused by a cement mortar water distribution pipe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1244532" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The dialysis encephalopathy syndrome. Possible aluminum intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15390004" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Reversible parkinsonism following heroin pyrolysate inhalation is associated with tetrahydrobiopterin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11496854" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Toxic leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25904688" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Heroin inhalation complicated by refractory hydrocephalus: A novel presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26644052" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Heroin inhalation complicated by refractory hydrocephalus: A novel presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1677142" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Spongiform leucoencephalopathy after inhaling heroin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1620347" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30792768" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chasing the wrong dragon: A new presentation of heroin-induced toxic leukoencephalopathy mimicking anoxic brain injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14677803" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A fatal case of spongiform leukoencephalopathy linked to "chasing the dragon".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9601960" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Toxic spongiform leucoencephalopathy after inhaling heroin vapour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977583" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hippocampal involvement due to heroin inhalation--"chasing the dragon".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18194689" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19542414" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16419370" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : "Chasing the dragon"--imaging of heroin inhalation leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20229208" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Toxic leukoencephalopathy after heroin abuse without heroin vapor inhalation: MR imaging and clinical features in three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27742371" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Leucoencephalopathy following abuse of sniffed heroin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36074113" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Two Cases Comparing the Presentations and Outcomes of Heroin-induced Toxic Leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10674060" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Chasing the dragon--neurological toxicity associated with inhalation of heroin vapour: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3419616" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Primary cerebellar brain abscess from nocardiosis in a heroin addict.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5695789" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Transverse myelitis associated with heroin addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17917867" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Unusual complications of heroin abuse: transverse myelitis, rhabdomyolysis, compartment syndrome, and ARF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4123187" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Heroin neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/690660" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Polyradiculoneuropathy associated with heroin abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5539919" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Limb compression and renal impairment (crush syndrome) complicating narcotic overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2997401" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Rhabdomyolysis and concomitant neurological lesions after intravenous heroin abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25925073" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acute fatal posthypoxic leukoencephalopathy following benzodiazepine overdose: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31309133" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : "CHOICES": An acronym to aid in delineating potential causes of non-metabolic, non-infectious acute toxic leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31309133" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : "CHOICES": An acronym to aid in delineating potential causes of non-metabolic, non-infectious acute toxic leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1247396" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hypoxic-ischemic leukoencephalopathy in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2234393" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : MRI demonstration of cortical laminar necrosis and delayed white matter injury in anoxic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11222791" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : MRI identification of early white matter injury in anoxic-ischemic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16971632" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Reversible delayed posthypoxic leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14748556" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The effects of toluene on the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10463369" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Toxic leukencephalopathy following "ecstasy" ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637976" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reversible spongiform leucoencephalopathy after inhalation of heated heroin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19515634" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Heroin vapor inhalation-induced spongiform leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21519216" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : 'Chasing the dragon': new knowledge for an old practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249600" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Chasing "chasing the dragon" with MRI: leukoencephalopathy in drug abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9036319" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Heroin inhalation and progressive spongiform leukoencephalopathy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
